Papageorgiou G - Search Results

1

Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma.

Skouteris N, Papageorgiou G, Fioretzaki R, Schizas D, Kykalos S, Tolia M, Charalampakis N. Skouteris N, et al. Among authors: papageorgiou g. Immunotherapy. 2023 May;15(7):487-502. doi: 10.2217/imt-2022-0225. Epub 2023 Mar 6. Immunotherapy. 2023. PMID: 36876442 Review.

2

Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.

Papageorgiou GI, Tsakatikas SA, Fioretzaki RG, Kosmas C. Papageorgiou GI, et al. Anticancer Drugs. 2021 Mar 1;32(3):330-336. doi: 10.1097/CAD.0000000000001021. Anticancer Drugs. 2021. PMID: 33229903

3

Immunotherapy for cholangiocarcinoma: a 2021 update.

Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Charalampakis N, et al. Among authors: papageorgiou g. Immunotherapy. 2021 Sep;13(13):1113-1134. doi: 10.2217/imt-2021-0126. Epub 2021 Jun 30. Immunotherapy. 2021. PMID: 34190581 Review.

4

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives.

Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Charalampakis N, et al. Among authors: papageorgiou g. World J Gastrointest Oncol. 2022 Jan 15;14(1):181-202. doi: 10.4251/wjgo.v14.i1.181. World J Gastrointest Oncol. 2022. PMID: 35116110 Free PMC article. Review.

5

Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer.

Papageorgiou GI, Skouteris N, Kosma A, Markouizou A, Charalampakis N. Papageorgiou GI, et al. Rev Recent Clin Trials. 2023;18(2):146-155. doi: 10.2174/1574887118666230412112136. Rev Recent Clin Trials. 2023. PMID: 37046193

6

Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.

Papageorgiou G, Skouteris N, Valavanis C, Stanc GM, Souka E, Charalampakis N. Papageorgiou G, et al. Rev Recent Clin Trials. 2023;18(4):304-312. doi: 10.2174/0115748871258042230921052344. Rev Recent Clin Trials. 2023. PMID: 37877150

7

PARP Inhibitors in Colorectal Malignancies: A 2023 Update.

Skouteris N, Papageorgiou G. Skouteris N, et al. Among authors: papageorgiou g. Rev Recent Clin Trials. 2023 Dec 6. doi: 10.2174/0115748871260815231116060817. Online ahead of print. Rev Recent Clin Trials. 2023. PMID: 38058097

8

Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.

Papageorgiou GI, Fergadis E, Skouteris N, Christakos E, Tsakatikas SA, Lianos E, Kosmas C. Papageorgiou GI, et al. Front Oncol. 2021 Dec 22;11:788809. doi: 10.3389/fonc.2021.788809. eCollection 2021. Front Oncol. 2021. PMID: 35004311 Free PMC article.

9

Perforated appendicitis induced by pembrolizumab: a case report and review of the literature.

Papageorgiou GI, Fergadis E, Skouteris N, Christakos E, Tsakatikas SA, Filippakou A, Papantoni E, Stanc G, Souka E, Valavanis C, Kosmas C. Papageorgiou GI, et al. Anticancer Drugs. 2022 Feb 1;33(2):208-213. doi: 10.1097/CAD.0000000000001247. Anticancer Drugs. 2022. PMID: 34538865

10

Central neurotoxicity induced by trastuzumab emtansine (T-DM1): a case report.

Papageorgiou GI, Symeonidis DG, Tsakatikas SA, Liatsos AD, Douglas KAA, Douglas VP, Moschos MM, Kosmas C. Papageorgiou GI, et al. Anticancer Drugs. 2021 Nov 1;32(10):1146-1149. doi: 10.1097/CAD.0000000000001117. Anticancer Drugs. 2021. PMID: 34232951

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

302 results

Search Page